Gautham Reddy 6 Christophe Corpechot 7 Susheela Carroll 8 Ke Yang 9 Daria Crittenden 8 Charles McWherter 9 , 1 Liver Institute Northwest, 2 California Pacific Medical Center, 3 Weill Cornell Medical College, New York, NY, 4 California Liver Reasearch Institiute, 5 Beth Israel Deaconess Medical Center, Boston, MA, 6 University of Chicago Medical Center, 7 Saint-Antoine Hospital, Paris, France, 8 CymaBay Therapeutics Inc, 9 CymaBay Therapeutics Background: Alkaline phosphatase (ALP) is an important marker in primary biliary cholangitis (PBC) associated with risk for disease progression
In an opinion published in the BMJ on July 21, 2025, Ellen Fallows noted the risks of prescribing GLP-1 medications to patients who already consume nutrient-poor diets, highlighting that malnutrition cases are already being reported in the U.S
Schwartz AR, Patil SP, Squier S, Schneider H, Kirkness JP, Smith PL
Pharmacokinetics and tolerability of a single dose of semaglutide, a human glucagon-like peptide-1 analog, in subjects with and without renal impairment